Bio Developments


Rocket Pharmaceuticals to acquire Renovacor

By Rachel Arthur

Rocket Pharmaceuticals, a late-stage, clinical biotech advancing a pipeline of genetic therapies for rare childhood disorders, will acquire Renovacor: helping it strengthen its position in AAV-based cardiac gene therapy.

Join us for our free-to-attend Bioprocessing 4.0 webinar!

Join us for our free-to-attend Bioprocessing 4.0 webinar!

By Rachel Arthur

What role does Bioprocessing 4.0 have to play in the ongoing energy crisis? How can we train and develop the right skills for the industry? These are just some of the questions we’ll ask in our free-to-attend webinar tomorrow!


WHO issues latest recommendations for COVID-19 booster doses

By Rachel Arthur

The WHO has updated its advice on COVID-19 booster doses: including recommendations on which groups should receive a second booster shot and how countries should plan around the upcoming availability of variant-specific vaccines.


Merck picks up another ADC agreement

By Ben Hargreaves

With speculation that Merck is lining up a multi-billion dollar acquisition in the ADC space, the company has agreed a second collaboration deal with Sichuan Kelun Pharmaceutical.

© GettyImages/aquaArts studio

Alnylam has obesity gene target in its sights

By Jane Byrne

Cambridge, Massachusetts based, Alnylam Pharmaceuticals, along with collaborators, has identified mutations in the INHBE gene linked with protection against abdominal obesity.


New investment in monkeypox vaccine assessment tools

By Rachel Arthur

The Coalition for Epidemic Preparedness Innovations (CEPI) will provide funding of up to $375,000 to the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the UK Health Security Agency (UKHSA) to support the development of laboratory tools...